Mitigating the Pro-inflammatory Phenotype of Obesity
Eligible age
18–79 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to examine the hypothesize that 4 weeks of sympathetic nerve activity (SNA) inhibition (oral clonidine) will cause a significant reduction in circulating blood concentrations and endothelial cell expression of inflammatory markers (e.g., TNF-α, IL-6). Our study is a prospective study using a randomized, double-blinded design to test 4 weeks of SNA blockade (oral clonidine) compared with a BP-lowering control condition (diuretic, hydrochlorothiazide) or a placebo.
Sponsor: University of Kansas Medical Center
You may qualify if…
- ✓ Male or Female, age 18-79
- ✓ Obese: BMI \> 30 m/kg2
- ✓ Hypertensive: blood pressure \>130/80
- ✓ Elevated insulin resistance (HOMA-IR \> 2.5)
- ✓ Waist circ: \>102 cm (men) and \>88 cm (women)
- ✓ Fasting glucose \< 126 mg/dL
- ✓ Fasting triglycerides \< 250 mg/dL
- ✓ HbA1c \< 6.5%
You may not qualify if…
- ✕ Current use of clonidine or beta-blockers
- ✕ Current smoker or History of smoking in the past 3 months.
- ✕ Hyperlipidemia: Fasting triglycerides \> 250 mg/dL
- ✕ Currently taking hypertension medication
- ✕ History of heart disease (e.g., myocardial infarction, stent, byass, heart attack, stroke, heart failure, valvular heart disease, cardiomyopathy)
- ✕ History of neurological disorders
- ✕ History of transplant
- ✕ Actively participating in other studies, except for a registry study.
Where it's recruiting
Kansas City
Source: ClinicalTrials.gov · NCT04934228 · last updated 2025-06-05